top of page
GynOnco Group Team
Writer
More actions
Profile
Join date: Aug 2, 2025
Posts (8)
Aug 16, 2025 ∙ 1 min
A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2
A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma (NRG-GY026)
20
0
Aug 16, 2025 ∙ 1 min
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Resp
A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NRG-GY036)
13
0
Aug 16, 2025 ∙ 1 min
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY019)
10
0
bottom of page